Compare Stocks: OLMA, AMLX, GMTX, and ABCL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.12 -0.7%	$6.89	$2.74 ▼ $11.65	$3.49B	1.2	9.40 million shs	8.18 million shs
AMLX Amylyx Pharmaceuticals	$35.11 +63.8%	$18.88	$7.63 ▼ $35.39	$2.39B	-0.21	2.04 million shs	23.92 million shs
GMTX Gemini Therapeutics	$80.05 +1.5%	$74.86	$1.16 ▼ $14.10	$3.47B	-0.12	189,291 shs	384,206 shs
OLMA Olema Pharmaceuticals	$10.65 -1.1%	$11.26	$5.34 ▼ $36.26	$930.10M	2.03	960,416 shs	960,508 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-1.58%	+19.91%	+73.11%	+176.54%	+144.01%
AMLX Amylyx Pharmaceuticals	-0.92%	-5.47%	+20.73%	+68.21%	+167.88%
GMTX Gemini Therapeutics	0.00%	+1.81%	+3.53%	+17.94%	+31.71%
OLMA Olema Pharmaceuticals	+1.32%	-9.80%	-6.10%	-17.79%	+95.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.12 -0.7%	$6.89	$2.74 ▼ $11.65	$3.49B	1.2	9.40 million shs	8.18 million shs
AMLX Amylyx Pharmaceuticals	$35.11 +63.8%	$18.88	$7.63 ▼ $35.39	$2.39B	-0.21	2.04 million shs	23.92 million shs
GMTX Gemini Therapeutics	$80.05 +1.5%	$74.86	$1.16 ▼ $14.10	$3.47B	-0.12	189,291 shs	384,206 shs
OLMA Olema Pharmaceuticals	$10.65 -1.1%	$11.26	$5.34 ▼ $36.26	$930.10M	2.03	960,416 shs	960,508 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-1.58%	+19.91%	+73.11%	+176.54%	+144.01%
AMLX Amylyx Pharmaceuticals	-0.92%	-5.47%	+20.73%	+68.21%	+167.88%
GMTX Gemini Therapeutics	0.00%	+1.81%	+3.53%	+17.94%	+31.71%
OLMA Olema Pharmaceuticals	+1.32%	-9.80%	-6.10%	-17.79%	+95.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.71	Moderate Buy	$12.83	15.41% Upside
AMLX Amylyx Pharmaceuticals	2.90	Moderate Buy	$28.75	-18.11% Downside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	2.71	Moderate Buy	$42.40	298.12% Upside

Current Analyst Ratings Breakdown

Latest OLMA, AMLX, GMTX, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $55.00
8/17/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$24.00 ➝ $30.00
8/13/2026	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$52.00 ➝ $46.00
8/11/2026	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $36.00
8/11/2026	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$12.00 ➝ $30.00
8/11/2026	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$59.00
8/6/2026	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $9.00
8/6/2026	ABCL AbCellera Biologics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $12.00
8/5/2026	AMLX Amylyx Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $26.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$66.17M	51.53	N/A	N/A	$3.23 per share	3.44
AMLX Amylyx Pharmaceuticals	$87.37M	44.77	N/A	N/A	$2.78 per share	12.63
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	11/5/2026 (Estimated)
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	N/A

Latest OLMA, AMLX, GMTX, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
GMTX Gemini Therapeutics	N/A	71.49	71.49
OLMA Olema Pharmaceuticals	0.01	8.86	8.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
AMLX Amylyx Pharmaceuticals	95.84%
GMTX Gemini Therapeutics	75.42%
OLMA Olema Pharmaceuticals	91.78%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
AMLX Amylyx Pharmaceuticals	10.90%
GMTX Gemini Therapeutics	12.90%
OLMA Olema Pharmaceuticals	12.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	306.61 million	219.53 million	Optionable
AMLX Amylyx Pharmaceuticals	200	111.42 million	99.28 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
OLMA Olema Pharmaceuticals	70	87.50 million	76.51 million	Optionable

OLMA, AMLX, GMTX, and ABCL Headlines

Recent News About These Companies

Olema Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:OLMA)

2 hours ago | marketbeat.com

JPMorgan Chase & Co. Lowers Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $46.00

August 15 at 2:42 AM | americanbankingnews.com

HC Wainwright Has Negative Outlook for OLMA Q3 Earnings

August 15 at 1:43 AM | americanbankingnews.com

Piper Sandler Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

August 13, 2026 | theglobeandmail.com

Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer

August 13, 2026 | markets.businessinsider.com

Olema Pharmaceuticals (OLMA) Receives a Buy from Goldman Sachs

August 13, 2026 | theglobeandmail.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price

August 13, 2026 | marketbeat.com

HC Wainwright Brokers Decrease Earnings Estimates for OLMA

August 13, 2026 | marketbeat.com

Citigroup Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price

August 13, 2026 | americanbankingnews.com

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down Following Weak Earnings

August 13, 2026 | americanbankingnews.com

Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at Citigroup

August 11, 2026 | marketbeat.com

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down on Disappointing Earnings

August 11, 2026 | marketbeat.com

Olema Pharmaceuticals Q2 Loss Widens

August 11, 2026 | finance.yahoo.com

Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

August 10, 2026 | finance.yahoo.com

Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results, Misses Estimates By $0.08 EPS

August 10, 2026 | marketbeat.com

Olema Pharmaceuticals (OLMA) Expected to Post Earnings on Monday

August 9, 2026 | americanbankingnews.com

Dimensional Fund Advisors LP Acquires 123,790 Shares of Olema Pharmaceuticals, Inc. $OLMA

August 8, 2026 | marketbeat.com

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 4, 2026 | globenewswire.com

Olema Pharmaceuticals (OLMA) Expected to Release Quarterly Earnings on Monday

August 3, 2026 | marketbeat.com

Defilade Capital Management L.P. Acquires 269,902 Shares of Olema Pharmaceuticals, Inc. $OLMA

August 3, 2026 | marketbeat.com

Janus Henderson Group PLC Boosts Holdings in Olema Pharmaceuticals, Inc. $OLMA

August 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA, AMLX, GMTX, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$11.12 -0.08 (-0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$11.08 -0.04 (-0.35%)

As of 07:59 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Amylyx Pharmaceuticals NASDAQ:AMLX

$35.11 +13.68 (+63.84%)

Closing price 04:00 PM Eastern

Extended Trading

$35.11 +0.00 (+0.00%)

As of 07:59 PM Eastern

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.

Gemini Therapeutics NASDAQ:GMTX

$80.05 +1.21 (+1.53%)

As of 08/17/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Olema Pharmaceuticals NASDAQ:OLMA

$10.65 -0.12 (-1.11%)

Closing price 04:00 PM Eastern

Extended Trading

$10.73 +0.08 (+0.76%)

As of 07:56 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OLMA, AMLX, GMTX, and ABCL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OLMA, AMLX, GMTX, and ABCL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OLMA, AMLX, GMTX, and ABCL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA, AMLX, GMTX, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Amylyx Pharmaceuticals NASDAQ:AMLX

Gemini Therapeutics NASDAQ:GMTX

Olema Pharmaceuticals NASDAQ:OLMA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OLMA, AMLX, GMTX, and ABCL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OLMA, AMLX, GMTX, and ABCL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OLMA, AMLX, GMTX, and ABCL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA, AMLX, GMTX, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Amylyx Pharmaceuticals NASDAQ:AMLX

Gemini Therapeutics NASDAQ:GMTX

Olema Pharmaceuticals NASDAQ:OLMA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools